The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles



Authors

Zaki Molvi, Martin G. Klatt, Tao Dao, Jessica Urraca, David A. Scheinberg, Richard J. O'Reilly

Correspondence

zaki.molvi@gmail.com; oreillyr@mskcc.org

In Brief

Phosphopeptides that are derived from genetic dependencies in hematologic malignancies and are presented by multiple human leukocyte antigen (HLA) alleles represent shared tumor antigens that could be targeted for cancer immunotherapy, but the immunogenicity of such phosphopeptides is not a general feature, which may be explained by the energetics of the peptide-HLA complex.